Combining low-cost, high-resolution radiography with dynamic imaging capabilities and design attributes to optimize workflow efficiency, the Chiropractic Straight Arm system may enhance musculoskeletal imaging.
The new Chiropractic Straight Arm (CSA) system with Dynamic Digital Radiography (DDR) has garnered 510(k) clearance from the Food and Drug Administration (FDA), according to 20/20 Imaging, a division of Konica Minolta Healthcare Americas, Inc.
The company said the DDR technology allows low-cost, high-speed capture of static and dynamic images. A cine loop with the DDR technology allows one view acquisition on conventional digital radiography to provide up to a 20-second snapshot of anatomical motion, according to 20/20 Imaging.
Other features of the compact CSA include detailed bone and soft tissue visualization with a 17” x 17” field of view detector as well as predetermined anatomy-specific patient positioning to help simplify workflow. The company emphasized that flexibility and range of motion of the CSA system accommodate a variety of patient positioning needs from standing to lying on a table and those using wheelchairs.
20/20 Imaging also noted the combination of CSA and DDR enables one to obtain dynamic views of the cervical spine during flexion and extension, a key attribute that can be helpful with the documentation of whiplash injuries.
“CSA with DDR is the next-generation imaging solution allowing chiropractors to examine and measure a patient’s biomechanics and musculoskeletal injury, including whiplash, and more confidently evaluate treatment follow-up,” noted Bob Salzman, the president of 20/20 Imaging. “Designed to boost clinical capabilities to the next level by capturing patient movement, CSA with DDR gives chiropractors the immediate results they need to make informed decisions faster.”
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Interventional Radiology Study Shows Low Breast Cancer Recurrence 16 Months After Cryoablation
March 29th 2024In a cohort of patients with invasive breast cancer and tumor sizes ranging between 0.3 to 9 cm, image-guided cryoablation was associated with a 10 percent recurrence rate at 16 months, according to research recently presented at the Society of Interventional Radiology (SIR) conference.